Transfer Of Value Disclosure
FINANCIAL INFORMATION:
The following describes the funding received from non-NHS organisations to support programmes of work that aim to improve the health and care system in the North East and North Cumbria:
| Organisations Involved | Start Date | End Date | Monetary Value | Reason for Benefit |
| Chiesi Farmaceutici and AHSN NENC | 01/02/2022 | 16/05/2022 | £5,000.00 | To develop the Pharm outcomes template for the Tees Valley Inhaler Project |
| OrionPharma (UK) Ltd and AHSN NENC | 01/02/2022 | 16/05/2022 | £5,400.00 | To develop the Pharm outcomes template for the Tees Valley Inhaler Project |
| AstraZeneca PLC and AHSN NENC | 01/02/2022 | 16/05/2022 | £26,400.00 | To deliver the pilot programme of work for the Tees Valley Inhaler project |
| GlaxoSmithKline and AHSN NENC | 01/02/2022 | 16/05/2022 | £5,400.00 | To develop the Pharm outcomes template as part of the Tees Valley Inhaler project |
| Sanofi | 31/03/2022 | 30/09/2023 | £37,479.28 | JWA to facilitate earlier diagnosis of Fabry, Pompe and Gaucher diseases through the use of disease prediction models using real-work data from Primary Care records (CDRC – rare diseases) |
| Sanofi | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Amgen Ltd | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Novartis Pharmaceuticals UK Ltd | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Daiichi Sankyo | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Amarin UK Ltd | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Sanofi (registered name Aventis Pharma Ltd) | 18/11/2022 | 31/03/2023 | £768.00 | Reimbursement costs for a guest speaker at a Sanofi event |
| Novartis Pharmaceuticals | 23/12/2022 | 23/12/2023 | £150,000 | Undertake medical education activities around holistic lipid management and prevention of CVD |
| Boehringer Ingleheim | 01/02/2022 | 30/09/2023 | 3000 Contracts | Grant/donation towards education and service development in support of Improving outcomes for Respiratory patients, Tees Valley inhaler project |
| Novartis Pharmaceuticals UK Limited | 20/10/2021 | 31/03/2024 | £111,294 | Support the implementation of the NHSE-Novartis collaboration project as part of the AHSN Network’s national lipid optimisation programme |
| Novartis Pharmaceuticals UK Limited | 01/04/2023 | 31/03/2024 | £198,000 | Sustain secondary care and primary care clinical roles, develop primary care lipid hub and embed projects supported by AHSN NENC CVD team |
| Novartis Pharmaceuticals UK Limited | 27/09/2022 | 26/04/2024 | £135,024 | Promote the use of the nationally endorsed lipid management pathway and service transformation work and promote adoption of best practice |
| Amarin UK Limited | 17/07/2023 | 19/10/2023 | £650 | Northern Lipid Forum |